Malignant progenitors from patients with CD87+ acute myelogenous leukemia are sensitive to a diphtheria toxin-urokinase fusion protein

Experimental Hematology

Volumn 30, Issue 11, 2002, Pages 1316-1323

  Frankel, Arthur E ^a   Beran, Miloslav ^b   Hogge, Donna E ^c   Powell, Bayard L ^a   Thorburn, Andrew ^a   Chen, Yong Q ^a   Vallera, Daniel A ^d  

^a WAKE FOREST SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^c BRITISH COLUMBIA CANCER AGENCY   (Canada)

^d UNIVERSITY OF MINNESOTA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DIPHTHERIA TOXIN UROKINASE FUSION PROTEIN; DIPHTHERIA TOXOID; UNCLASSIFIED DRUG; UROKINASE RECEPTOR;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGED; ARTICLE; CELL PROLIFERATION; CLONOGENIC ASSAY; CONTROLLED STUDY; DENSITY GRADIENT CENTRIFUGATION; DRUG CYTOTOXICITY; FEMALE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IMMUNOPHENOTYPING; LEUKEMIA CELL; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN EXPRESSION; RECEPTOR DENSITY; STEM CELL;

ACUTE DISEASE; ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; CELL DIVISION; DIPHTHERIA TOXIN; DRUG DELIVERY SYSTEMS; DRUG SCREENING ASSAYS, ANTITUMOR; FEMALE; HUMANS; LEUKEMIA, MYELOID; MALE; MIDDLE AGED; NEOPLASM PROTEINS; RECEPTORS, CELL SURFACE; RECOMBINANT FUSION PROTEINS; TUMOR STEM CELL ASSAY; TUMOR STEM CELLS; URINARY PLASMINOGEN ACTIVATOR;

EID: 0036840044     PISSN: 0301472X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0301-472X(02)00925-6     Document Type: Article

References (21)

1. Estey E.H. Treatment of relapsed and refractory acute myelogenous leukemia. Leukemia. 14:2000;476.
2. Marie J.P. Drug resistance in hematologic malignancies. Curr Opin Oncol. 13:2001;463.
3. Frankel A.E., Powell B.L., Vallera D.A.et al. Chimeric fusion proteins - diphtheria toxin-based. Curr Opin Invest Drugs. 2:2001;1294.
4. Frankel A.E., Rossi P., Kuzel T.M.et al. Diphtheria fusion protein therapy of chemoresistant malignancies. Curr Cancer Drug Targets. 2:2002;19.
5. Feuring-Buske M., Frankel A., Gerhard B.et al. Variable cytotoxicity of diphtheria toxin 388-granulocyte-macrophage colony-stimulating factor fusion protein for acute myelogenous leukemia stem cells. Exp Hematol. 28:2000;1390.
6. Feuring-Buske M., Frankel A.E., Alexander R.L.et al. A diphtheria toxin-interleukin 3 fusion protein is cytotoxic to primitive acute myeloid leukemia progenitors but spares normal progenitors. Cancer Res. 62:2002;1730.
7. Ploug M., Ellis V. Structure-function relationships in the receptor for urokinase-type plasminogen activator. FEBS Lett. 349:1994;163.
8. Fazioli F., Blasi F. Urokinase-type plasminogen activator and its receptor. new targets for anti-metastatic therapy? Trends Pharm Sci. 15:1994;25.
9. Jardi M., Ingles-Esteve J., Burgal M.et al. Distinct patterns of urokinase receptor (uPAR) expression by leukemic cells and peripheral blood cells. Thromb Haemost. 76:1996;1009.
10. Lanza F., Castoldi G.L., Castagnari B.et al. Expression and functional role of urokinase-type plasminogen activator receptor in normal and acute leukaemic cells. Br J Haematol. 103:1998;110.
11. Vallera D.A., Li C., Jin N.et al. Targeting urokinase-type plasminogen activator receptor on human glioblastoma tumors with diphtheria toxin fusion protein DTAT. J Natl Cancer Inst. 94:2002;597.
12. Ramage J.G., Vallera D.A., Black J.H.et al. The diphtheria toxin/urokinase fusion protein DTAT is selectively toxic to CD87 expressing leukemic cells. Leukemia Res. in press:2002.
13. Hogge D.E., Willman C.L., Kreitman R.J.et al. Malignant progenitors from patients with acute myelogenous leukemia are sensitive to a diphtheria toxin-granulocyte-macrophage colony-stimulating factor fusion protein. Blood. 92:1998;589.
14. Schiffer C.A. Acute myeloid leukemia in adults. where do we go from here? Cancer Chemother Pharmacol. 48(suppl. 1):2001;S45.
15. Perentesis J.P., Waddick K.G., Bendel A.E.et al. Induction of apoptosis in multidrug-resistant and radiation-resistant acute myeloid leukemia cells by a recombinant fusion protein directed against the human granulocyte-macrophage colony-stimulating factor receptor. Clin Cancer Res. 3:1997;347.
16. Kroon M.E., Koolwijk P., van der Vecht B.et al. Urokinase receptor expression on human microvascular endothelial cells is increased by hypoxia. implications for capillary-like tube formation in a fibrin matrix Blood. 96:2000;2775.
17. Ragno P., Montuori N., Covelli B.et al. Differential expression of a truncated form of the urokinase-type plasminogen activator receptor in normal and tumor thyroid cells. Cancer Res. 58:1998;1315.
18. Plesner T., Ralfklaer E., Wittrup M.et al. Expression of the receptor for urokinase-type plasminogen activator in normal and neoplastic blood cells and hematopoietic tissue. Am J Clin Pathol. 102:1994;835.
19. Sillaber C., Baghestanian M., Hofbauer R.et al. Molecular and functional characterization of the urokinase receptor on human mast cells. J Biol Chem. 272:1997;7824.
20. Ippoliti R., Lendaro E., Benedetti P.A.et al. Endocytosis of a chimera between human pro-urokinase and the plant toxin saporin. an unusual internalization mechanism FASEB J. 14:2000;1335.
21. Alexander R.L., Ramage J., Kucera G.L.et al. High affinity interleukin-3 receptor expression on blasts from patients with acute myelogenous leukemia correlates with cytotoxicity of a diphtheria toxin/IL-3 fusion protein. Leukemia Res. 25:2001;875.